BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Fortis Life Sciences and Deliver Biosciences today announced that Fortis named Deliver Biosciences as the inaugural recipient of the 2026 Fortis Grant Series. The Fortis Grant featured AbNano VHH Discovery services as an initiative to create greater opportunities for organizations using new technologies to develop high-potential therapeutic programs.

Many serious diseases remain difficult to treat because the biological targets that drive them are often difficult to access with conventional antibodies. Large antibody formats can struggle to penetrate dense tissues such as solid tumors, limiting their therapeutic potential. VHH antibodies offer a promising alternative. Their smaller size, low immunogenicity, and stability can help them move through tissue more effectively, bind with precision, and support new classes of treatments.  

For researchers and drug developers, this enables faster development timelines, reduced biological barriers, enhanced targeting precision, and new opportunities across cancer, autoimmune disease, gene therapy, and targeted drug delivery.

The Fortis Grant Series gives ...